drugset / Trial / NCT04706923
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Timeline
- Start
- 2021-08-16
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brincidofovir | Other / unclassified | 0.2 mg/kg | Intravenous |
| Subject | Brincidofovir | Other / unclassified | 0.3 mg/kg | Intravenous |
| Subject | Brincidofovir | Other / unclassified | 0.4 mg/kg | Intravenous |